-
China’s Government Work Report Highlights Biomedicine Innovation and Healthcare Reforms
•
Chinese Premier Li Qiang presented a concise Government Work Report at the Second Session of the 14th National People’s Congress (NPC) on March 5. The report outlined key focuses for the biomedicine sector, emphasizing the acceleration of innovation to stimulate economic recovery. This includes advancements in cutting-edge fields such as…
-
EMA Reviews Datopotamab Deruxtecan Filings from AstraZeneca and Daiichi Sankyo for Oncology Indications
•
The European Medicines Agency (EMA) has accepted for review two oncology filings for the antibody-drug conjugate (ADC) datopotamab deruxtecan, developed jointly by UK-based AstraZeneca (AZ; NASDAQ: AZN) and Japan’s Daiichi Sankyo (TYO: 4568). The indications submitted for review are for the treatment of locally advanced or metastatic nonsquamous non-small cell…
-
Pfizer’s Cibinqo Secures NMPA Approval for Expanded Use in Atopic Dermatitis
•
The National Medical Products Administration (NMPA) has released drug approval certificate delivery information that points to a new indication approval for Pfizer (NYSE: PFE)’s JAK1 inhibitor Cibinqo (abrocitinib), a small molecule targeted therapy. This approval expands the drug’s use to include the treatment of moderate to severe atopic dermatitis (AD)…
-
China Aims to Insure 80% of Newborns with Basic Medical Insurance by 2024
•
The National Healthcare Security Administration (NHSA) and the National Health Commission (NHC), along with three other bureaus, have issued a Notice on “Carrying out the Special Action for Children to Participate in Basic Medical Insurance (BMI)”. The notice outlines an ambitious target to ensure that 80% of newborns in China…
-
Novartis Gene Therapy Zolgensma Shows Continued Benefits in Broader SMA Patient Group
•
Swiss pharmaceutical giant Novartis (NYSE: NVS) has presented Phase III data this week, demonstrating that the clinical benefits of its gene therapy Zolgensma (onasemnogene abeparvovec) for spinal muscular atrophy (SMA) extend beyond patients up to 2 years of age. The new study has shown similar benefits in older children, including…
-
Bitterroot Bio and Biotheus Inc. Join Forces to Develop Therapies for Cardiovascular Diseases
•
California-based biotechnology company Bitterroot Bio has announced the signing of a multi-year research collaboration agreement with China’s Biotheus Inc. The partnership aims to explore the development of innovative drugs that modulate the immune system and inflammatory responses, with a specific focus on targeting cardiovascular diseases (CVDs). By combining Bitterroot’s knowledge…
-
Luye Pharma Initiates Phase III Clinical Trial for Irinotecan Liposome Injection in Small-Cell Lung Cancer
•
Luye Pharma Group (HKG: 2186), a China-based pharmaceutical company, has announced the enrollment of the first patient in a Phase III clinical study for its irinotecan liposome injection, LY01610. The Phase III study, which is multi-center, randomized, open-label, and parallel-designed, aims to evaluate the efficacy and safety of LY01610 in…
-
Henlius Biotech Forecasts First-Ever Profit in 2023 Driven by Sales Growth and Efficient Management
•
Shanghai Henlius Biotech Inc., (HKG: 2696), a China-based biopharmaceutical company, has released a positive profit forecast, anticipating a minimum profit of RMB 500 million (USD 72.4 million) in 2023, marking the company’s first profitable year. This forecast is attributed to the sustained sales growth of its products Hanquyou (trastuzumab injection,…
